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ABSTRACT
Objective: The objective of this evidence-based medicine analysis is to determine whether or
not a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols
(FODMAPs), decreases overall symptoms in patients with irritable bowel syndrome (IBS).
Study Design: A systematic review including three randomized control trials (RCTs), which
were conducted between the years 2014 and 2019.
Data Sources: The RCTs used were located through PubMed. All articles were selected from
peer-reviewed journals that directly related to the clinical question and patient centered
outcomes.
Outcome Measured: A reduction in symptoms related to IBS was measured using the IBSSymptom Severity Scale (IBS-SSS) and the Visual Analog Scale (VAS). The IBS-SSS is based
on a scale from 0-500 mm, while the VAS is scaled from 0-100 and 0-300 mm. Higher scores are
correlated with more extreme IBS symptoms on both scales.
Results: Results reported by Bohn et al. revealed a decrease from baseline in the IBS-SSS of
78.0 (24%) in the low-FODMAP diet (p < 0.001) and a decrease of 66.0 (22%) in the alternative
IBS diet (p <0.001). In the RCT conducted by Patcharatrakul et al., a low-FODMAP diet
decreased symptoms according to the VAS by 22.7 mm (37.1%) (p < 0.001), whereas the control
did not reach statistical significance (p = 0.30). Halmos et al. reported an average decrease in
symptom scores by 13.2 mm (36.67%) in the low-FODMAP diet (p < 0.001), compared to an
increase in symptoms on the control diet by 8.9 mm (24.72%) (p < 0.001).
Conclusions: The studies reported statistically significant findings, proving the low-FODMAP
diet decreased symptoms in patients with IBS, according to the IBS-SSS and VAS. With strong
evidence to support the efficacy of the low-FODMAP diet, further studies should be conducted
to modify, understand, and further improve the diet.
Key Words: Irritable bowel syndrome, symptoms, FODMAP, adult.
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INTRODUCTION
Irritable bowel syndrome (IBS) is defined by the manifestation of altered stooling,
accompanied by gastrointestinal (GI) discomfort and pain. The main difference between IBS and
most other GI disorders is the absence of any pathological disease or clinical evidence of disease,
therefore termed a functional disorder.1 IBS can be further classified into subcategories, by
predominating symptoms of diarrhea, constipation, or a combination of both, known as IBS-D,
IBS-C, or IBS-M respectively. IBS has an estimated prevalence of 10% to 23%, with females
being affected one and a half to two times more frequently than males.2 Symptoms are known to
differ between men and women, with men reporting more diarrhea and women experiencing
more abdominal pain and constipation.1 More than half of the patients with IBS report
experiencing their first symptoms prior to 35 years old, with a decreasing prevalence with age.3
In the United States, IBS is among the most frequently diagnosed GI disorder. The direct
costs of IBS are estimated to be $1.35 billion, while indirect costs are estimated to be $205
million.4 IBS is responsible for up to 50% of GI consults with an estimated 2.4 to 3.5 million
annual physician visits per year in the United States.5,6 Patients with IBS are hospitalized at a
greater rate than other individuals, accounting for 25% to 30% of costs related to IBS.5 These
individuals undergo two to three times more cholecystectomies, double the amount of
hysterectomies and appendectomies, and about half are known to receive an unnecessary
ultrasound.5 Therefore, these patients are at higher risk for enduring unnecessary testing during
the diagnosis and treatment of IBS.
The diagnosis of IBS is based on the Rome III criteria, which deduces that symptoms
should be present for six months before the diagnosis, with symptoms occurring during the last
three months. Patients meet the criteria if they experience intermittent abdominal pain at the
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minimum of one day per week for the past three months, with two or more of the additional
components: symptoms related to stooling, associated with a change in stool consistency or
frequency of stool.7 Without pathological evidence of the disease, the diagnosis can be very
difficult.
Though little supporting evidence exists regarding the causes of IBS, research suggests
interactions between abnormal motility, brain-gut interaction, food intolerances, and
psychosocial distress may be components of the disease.1 The lack of understanding regarding
the etiology and pathophysiology has compromised the ability to develop efficacious treatments.
FDA-approved treatments of IBS include 5-HT3 receptor antagonists such as ondansetron,
rifaximin, and lubiprostone.8 These treatments reveal minimal benefit over the placebo, placing
emphasis on the need for future investigation of treatments for IBS.8 Given that an estimated
66% of patients associated diet to an exacerbation in symptoms of IBS, a diet low in fermentable
oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) has been developed
and increasingly utilized in the management of IBS.4
FODMAPs are poorly-absorbed small chains of carbohydrates that can increase the
transit time for water and fermentable substances in the colon and intestines. This leads to excess
formation of gas and distention of the GI lumen. Some examples of high-FODMAP foods
include beans, apples, and garlic; while low-FODMAP foods include oranges, lactose-free milk,
and gluten-free bread. The use of diet modification in the treatment of IBS can decrease adverse
side effects that the use of pharmacotherapy could create, while decreasing the cost of treatment
and the need for hospital visits and unnecessary testing.
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OBJECTIVE
The objective of this evidence-based medicine analysis is to determine whether or not “a
diet low in FODMAPs decreases the overall symptoms of IBS”.
METHODS
The randomized control trials (RCTs) systematically reviewed were selected based on
credibility, correlation to the clinical question, and an emphasis on patient-oriented outcomes.
All RCTs were obtained from PubMed using the keywords of “irritable bowel syndrome”,
“symptoms”, “FODMAP”, and “adult”. Inclusion criteria was composed of articles published in
the English language, peer-reviewed journals, publication within the last ten years, and an adult
population. The exclusion criteria encompassed languages other than English, publication prior
to 2011, secondary research, pediatric populations, inflammatory bowel disease (IBD), books, or
documents. The results were reported via p-values and changes in scores from the IBS-SSS and
VAS from baseline.
The sample population of the current review includes individuals diagnosed with IBS
according to the Rome III criteria from selective populations ranging from 18 to 70 years old. A
low-FODMAP diet was the intervention in all three studies. The controls included a traditionally
recommended diet for IBS, a frequently recommended diet, and an Australian diet. Studies
conducted by Bohn et al. and Patcharatrakul et al. were single-blinded RCTs, while the study
conducted by Halmos et al. was also a single-blinded RCT with the addition of a cross-over trial.
The demographics and characteristics regarding the RCTs is summarized in Table 1.
OUTCOMES MEASURED
All outcomes were assessing a decrease in patient-reported symptom severity during a
trial of a low-FODMAP diet. The study performed by Bohn et al. used the IBS-SSS to evaluate
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symptom severity, which is a composite score of abdominal pain/frequency, intensity, and
dissatisfaction with bowel habits. Participants with an IBS-SSS reduction ≥ 50 points, on a scale
from 0-500, were termed as “responders”.8 The studies conducted by Patcharatrakul et al. and
Halmos et al. used the VAS to evaluate symptom severity and changes from baseline, measured
in millimeters (mm). The VAS is a composite score of overall GI symptoms, abdominal pain,
flatulence, bloating, and dissatisfaction with the consistency of stool. A responder was identified
by a decrease in daily symptoms of 30% or more after 4 weeks of the intervention by
Patcharatrakul et. al and a change of 10 mm or greater, according to Halmos et al. A higher score
is indicative of more severe symptoms, according to both scales.
Table 1. Demographics and Characteristics of Included Studies
Study

Type

#
Patients
67
patients
included
in final
data

Age
(yrs)
18-70
y.o.

Inclusion Criteria

Exclusion Criteria

Bohn9
(2015)

Parallel
, multicenter
singleblind
RCT

Dx with Rome III criteria for
IBS, ages 18-70 y.o.
Probiotics, routinely used IBS
meds including antidepressants
were allowed if taken regularly
throughout study, with an
established use for at least a
month prior to initiation of
study.

Severe liver,
neurologic, cardiac,
or psychiatric
diseases, other GI
disorders, strict
dietary restrictions
(exception: lactosereduced diets were
allowed).

Patchara
trakul10
(2019)

Singleblind
RCT

62
patients
included
in final
data

18-70
y.o.

Singleblinded
RCT,
with
crossover
trial

38
patients
included
in final
data

23-60
y.o.

Dx according to Rome III
criteria for IBS, ages 18-70 y.o.
with moderate-severe
symptoms.
No use of probiotics,
prebiotics, antibiotics, or
symbiotics for 4 weeks
prior/during the study.
Required to be on stable
treatment.
Dx according to Rome III
criteria for IBS. Cannot be
using any pharmacologic
therapy for IBS (laxatives/antidiarrheals). Patients must not
have had prior IBS dietary
counseling.

Previous surgery of
GI tract (exception:
appendectomy/hemor
rhoidectomy).
Presence of IBD/GI
malignancy, celiac
disease, heart, liver,
neurological,
psychological, or
lung diseases.
Celiac disease,
previous abdominal
surgery,
comorbidities (i.e.
diabetes), or presence
of organic disease

Halmos
11
(2014)

W/
D
8

Interve
ntions
Low
FODMA
P diet
vs.
alternati
ve IBS
diet

4

Extensiv
e dietary
advice +
lowfodmap
diet vs.
brief
advice +
alternati
ve diet
Low
FODMA
P diet
vs.
Australi
an diet.

7
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RESULTS
Bohn et al. conducted a parallel, multi-center single-blinded RCT in Sweden, which
included 67 female patients ranging from 18-70 years old in the final data.9 All patients were
diagnosed with moderate to severe IBS according to the Rome III Criteria with an IBS-SSS ≥
175.9 The inclusion and exclusion criteria can be reviewed in Table 1.9 Eight participants
withdrew from the study and were not included in the final data, amounting to less than 20% loss
to follow-up.9 The intervention was four weeks long, with patients following a low-FODMAP
diet (n = 33) or another frequently recommended diet in the treatment of IBS (n = 34).9 Patients
in the low-FODMAP diet were provided with a detailed dietary guide of prohibited foods (onion,
wheat, lactose, fructose) and replacement options, with a greater emphasis on avoiding particular
food.9 The recommended diet encompassed avoiding large meals, caffeine, gas-producing food
and insoluble fiber, with a greater emphasis on the timing and amount of meals.9
The primary outcome focused on symptom reduction, which was accomplished in both
groups, with P-values < 0.001 proving valuable information.9 Of the 33 patients with IBS, about
58% (n=19) of patients on the low-FODMAP and 50% (n=17) of patients on the alternative IBS
diet, were considered responders.9 All subjects, whether responders or non-responders, were
consuming equivalent levels of FODMAPs by day 29 of the study.9 Changes from baseline
scores of 78 (24%) and 66 (22%) were seen within the IBS-SSS, in the low-FODMAP diet and
alternative IBS diet, respectively. Individually, the diets show significant results (p < 0.001),
while the p-value in between intervention groups was insignificant (p = 0.62).8 The results are
summarized in Table 2 below.
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Table 2. Change in Symptom Severity according to IBS-SSS9
Baseline
Week 4
Change
P-value
mean ± SD
mean ±
from
SD
baseline
Low FODMAP diet
324 ± 69
246 ± 127
- 78 (24%)
< 0.001
(n = 33)
Traditional IBS diet
302 ± 61
236 ± 78
- 66 (22%)
< 0.001
(n = 34)

6

P-Value between
intervention groups
0.62

Patcharatrakul et al. conducted a similar study assessing how dietary counseling in
conjunction with specific diets, can decrease symptom severity in patients with IBS.10 Four
patients were lost to follow-up, amounting to less than 20%, and not included in the final data.10
This data included 62 female patients ranging from 18-70 years old who were recruited from an
outpatient clinic in Bangkok, Thailand diagnosed with moderate to severe IBS according to the
Rome III Criteria.10
Patients were not permitted to use probiotics, prebiotics, symbiotics, or antibiotics for the
month prior, or throughout the study.10 Those with previous GI surgery, not including an
appendectomy or hemorrhoidectomy; IBD; GI malignancy; celiac disease; heart, liver,
neurological, psychological, or lung diseases were excluded from the study.10
This single-blinded RCT placed patients in either an experimental group, following a
low-FODMAP diet (n=30), or in the control group, following a frequently recommended diet
(n=32).10 The control group received less than five minutes of dietary advice recommending
avoidance of large meals and GI distress food triggers; the term “FODMAP” was not used.10 The
experimental group received 30 minutes of personalized recommendations on how to identify
high-FODMAP foods and alternative replacements for trigger foods in their diary; informative
pamphlets reinforced the information.10 At the conclusion of the study, eighteen (60%) patients
in the experimental group and nine (28%) patients in the control group, fit the criteria for being a
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responder (p = 0.001).10 At baseline, both groups had similar VAS scores, but at the completion
of the study, only the low-FODMAP group (38.5 ± 20.0) had a significantly lower symptom
score than the frequently recommended diet (53.5 ± 1.92) (p <0.01).10 The symptom change from
baseline in the low-FODMAP group was approximately 37% (p <0.001), with a statistically
insignificant change in symptoms of only approximately 5% (p = 0.30) in the frequently
recommended diet.10 The results are summarized in Table 3 below.
Table 3. Change in Symptom Severity according to VAS (0-100)10
Baseline
Week 4
Change
P-value
mean ± SD
mean ± SD
from
baseline
Low-FODMAP
61.2 ± 21.0
38.5 ± 20.0
- 22.7
< 0.001
diet (n = 30)
(37.1%)
Frequently
56.3 ± 17.8
53.5 ± 19.2 - 2.8 (4.97%)
0.30
Recommended
diet (n = 32)

P-Value post
intervention,
between groups
0.006

Halmos et al. conducted a single-blinded RCT, with a cross-over trial that included 30
patients with IBS and 8 healthy control patients, ranging from 23 to 60 years old.11 Patients were
diagnosed according to the Rome III criteria for IBS.11 The inclusion and exclusion criteria can
be reviewed in Table 1.
The study had three phases each of 21 days: treatment vs control, “wash-out period,” and
reversed control vs treatment, respectively. Treatment consisted of following a low-FODMAP
diet, and the control group followed an Australian diet; the third phase directed participants to
the alternate condition they had not had previously.11 In this study, all the meals and snacks were
provided in unlimited quantities.11 The primary outcome measured was a change from baseline
in GI symptom severity using the VAS.11
At baseline, patients with IBS averaged a score of 36.0 mm on the VAS (p < 0.001).11
After day seven, patients in the low-FODMAP group averaged decreased scores at 22.8 mm (p <
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0.001) on the VAS, while those on the Australian diet showed increased scores at 44.9 mm on
the VAS (p < 0.001).11 Differences between the groups were statistically significant (p <
0.001).11 Scores at day 21 were reported based on a 0-300 mm VAS score and were not included
in the analysis as they could not be accurately interpreted.11 Throughout the crossover study, 21
of the 30 patients with IBS (70%) were identified as responders, with improvement of 10 mm or
more in overall GI symptoms according to the VAS.11 The results are summarized in Table 4
below.
Table 4. Change in Symptom Severity According to VAS (0-100)11
Baseline
Last 14
Change from
P-Value
Mean
days*
baseline (mm)
(mm) ± SD (mm) ± SD
Low
36.0
22.8
- 13.2 (36.67%) p < 0.001
FODMAP (29.5-42.5) (16.7-28.8)
diet
Australian
diet

36.0
(29.5-42.5)

44.9
(36.6-53.1)

+ 8.9 (24.72%)

P-Value post
intervention,
between groups
p < 0.001

p < 0.001

DISCUSSION:
Proper understanding of the etiology and pathophysiology of IBS is necessary to facilitate
beneficial medical treatment to relieve patients’ symptoms, but this has yet to be achieved. As
such, a non-pharmacologic intervention, such as a low-FODMAP diet, can be advantageous. If
enough evidence suggests the low-FODMAP diet is effective then patient costs for
pharmacotherapy and the need for insurance company approvals will decrease. Yet, studies
reviewed have limitations and possible confounding factors, warranting ongoing research in this
area.
With a known trigger of IBS symptoms being related to food consumption, the current
review assessed the efficacy of a low-FODMAP diet in reducing symptoms of IBS. Bohn et al.
reported statistically significant improvements in scores according to the IBS-SSS using the low-
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FODMAP diet, with 50% of patients experiencing greater than a 50% reduction in their
symptoms. Results further concluded that patients with IBS-D responded more favorably to the
low-FODMAP diet, than those with IBS-C.9 While the low-FODMAP diet and alternative IBS
diet were successful in reducing symptoms, a high P-value between intervention groups (p =
0.62), suggests little difference in outcomes for participants following either of the diets.9
Potential confounds to this study include the population selected (female adults from Sweden)
and permitted use of regimented probiotics and pharmacotherapy throughout the study. Given
the similar efficacy in reducing symptoms, noting a change from baseline of 24% in the lowFODMAP diet and 22% in the alternative IBS diet, these interventions should be evaluated in
conjunction for future studies.
The study conducted by Patcharatrakul et al. revealed that the low-FODMAP diet
significantly improved the symptoms by 50-80%, in comparison to a frequently recommended
diet, which did not reach clinical significance in reducing symptoms.10 The sample population
focusing on females from chosen clinics in Bangkok, Thailand limits the generalizability of these
results to persons of similar culture and care.10 Another limiting factor is the exclusion from the
use of pharmacotherapy prior to or during the study.
In contrast to the study by Halmos et al. which provided participants with meals, the
study by Patcharatrakul et al., simulated real-life experiences where patients had to plan and
prepare their own meals after appropriate dietary advice was given. While personalized dietary
advice likely inflated the change in score from baseline, the idea of teaching these patients longterm, beneficial habits can be very useful. These findings offer valuable direction for future
research, with extensive symptom reduction in the low-FODMAP diet.
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Additional noteworthy conclusions were reported by Halmos et al., where patients with
IBS consuming the low-FODMAP diet experienced more than a 50% reduction in symptoms.11
The resolution of symptoms experienced by the patients was seen almost instantaneously, with
the peak symptom control being achieved by day seven.11 Halmos et al. reported significant
symptom resolution across all subclasses of IBS following a low-FODMAP diet.11 The study
reports a 22% decrease in symptom severity when comparing the effects of a low-FODMAP diet
with a typical Australian diet, where symptoms worsened.11
While Halmos et al. delineated notable positive findings, this study has several potential
confounds, limitations, and lacks generalizability. Prohibiting the use of pharmacotherapy and
providing meals throughout this intervention makes the study less like typical non-study
conditions.11 However, by preparing the meals for participants, perhaps, a truer evaluation of the
intervention itself is revealed. Additionally, Halmos et al. concludes that significant blinding was
achieved by avoiding the use of the word “FODMAP”, yet 83% of patients in the low-FODMAP
groups were able to guess their diet, which could have introduced bias. Although data and
conclusions reported by Halmos et al. support the efficacy of the low-FODMAP diet, it is
unclear why data was reported arbitrarily from the last 14 days of the study, instead of day
twenty-one of the study. Furthermore, it is unclear why the overall conclusions from day twentyone were reported and drawn from a VAS scored on a 0-300 mm scale, versus the rest of the
study, which uses a 100 mm scale.
Based on the statistically significant, yet cautioned results, the Halmos et al. findings
should be used in conjunction with the other studies to better understand the low-FODMAP diet.
Overall, all three studies were dichotomous, randomized, single-blinded trials and could have
stronger validity with double-blinded trials. While limitations and lack of generalizability are
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present across all studies, these findings offer valuable direction for future research regarding
low-FODMAP diets.
CONCLUSION
With few proven efficacious treatments, this systematic review highlights the validity and
benefits of the low-FODMAP diet in the treatment of IBS. Results stated by Bohn,
Patcharatrakul, and Halmos, et al., mutually report statistically significant decreases in the
symptom scores from baseline of patients with IBS, according to the IBS-SSS and VAS in as
little as seven days.
With females being affected to a much higher degree than males, the studies by Bohn and
Patcharatrakul et al. focused only on adult females. Future studies should also investigate males
and pediatric populations. The incorporation of diverse samples of populations, diets, and
geographical locations should be used to further understand trends about the disease.
Future directions for research should include a RCT conducted through a mobile
application, allowing patients to attend nutritional counseling sessions and record their meals,
while also reporting their symptoms according to the IBS-SSS. The use of logging food and
symptoms post-consumption could be used to identify what foods may worsen patients’
symptoms. The nutritionists’ lessons would encompass information regarding IBS and the lowFODMAP diet, what foods to avoid, and alternative options to eat when they have cravings. By
hypothetically launching the application through GI clinics internationally, a larger patient
sample would be reached. All in all, the studies reviewed described efficacious treatments
reflecting symptom severity reduction, and considerations for overcoming these studies’
limitations in the future.
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